Obesity medicine association announces major updates to its adult obesity algorithm

May 15, 2019

DENVER -- May 15, 2019 -- The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

"Obesity is much more than an increase in body fat," said Dr. Harold Bays, MD, FTOS, FACC, FACE, FNLA, FOMA, an OMA Board of Trustee member, the Medical Director of L-MARC Research Center in Louisville, Kentucky and the co-chair of the Adult Obesity Algorithm. "Obesity is a disease that both directly and indirectly contributes to heart disease, diabetes, high blood pressure, abnormal fats in the blood, fatty liver and even cancer. The 2019 OMA Adult Obesity Algorithm helps clinicians combat this expansive disease that affects more than 70 percent of the population by providing a comprehensive roadmap for treatment and evaluation."

The OMA Adult Obesity Algorithm is a resource for health care professionals looking for evidence-based and clinical guidance for managing the chronic disease of Obesity. Contents of the OMA Adult Obesity Algorithm include:The OMA Adult Obesity Algorithm was originally released in 2013 and undergoes a rigorous review each year by a committee representing a diverse range of clinicians, allied health professionals, clinical researchers and academicians, intended to reflect a multidisciplinary and balanced group of experts in obesity science, evaluation and treatment. All contents in the OMA Adult Obesity Algorithm are based upon scientific evidence, supported by medical literature and derived from clinical experiences.

"Obesity is a disease that is complex and is not easily treated by simply adjusting a person's lifestyle choices. The OMA works tirelessly to provide high quality educational programs, tools and other resources to supply health care providers with powerful information to help improve patient care," says Claudia Randall, MBA, and Executive Director of the Obesity Medicine Association.

"The science and clinical management of obesity is rapidly evolving," said Dr. William McCarthy, MD, founder of the Continuing Medical Education program at Potomac Hospital in Woodbridge, Virginia and co-chair of the OMA Adult Obesity Algorithm. "To keep up, we really need at least yearly updates. That is what we have done."
-end-
The 2019 OMA Adult Obesity Algorithm is available in print, in a keyword friendly searchable e-book format and in a presentation PowerPoint format. To learn more, visit http://www.obesitymedicine.org/obesity-algorithm.

About the Obesity Medicine Association

The Obesity Medicine Association (OMA) is the largest organization of physicians and other healthcare providers dedicated to the clinical treatment of the disease of Obesity. OMA members are clinical experts in Obesity Medicine who use a comprehensive, scientific and individualized approach when treating Obesity, which helps patients achieve improved health and weight goals. Learn more at http://www.obesitymedicine.org.

Obesity Medicine Association

Related Diabetes Articles from Brightsurf:

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Diabetes, but not diabetes drug, linked to poor pregnancy outcomes
New research indicates that pregnant women with pre-gestational diabetes who take metformin are at a higher risk for adverse pregnancy outcomes -- such as major birth defects and pregnancy loss -- than the general population, but their increased risk is not due to metformin but diabetes.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.